Effect of ligustrazine on cardiac inflammation in rats with type 2 diabetes mellitus

Xin-yuan ZHAO,Kui XU,Cai-rong LI,Juan LI,Feng-ping LIN,Cai-yan LI,Jia-zhong SUN,Xiao CHEN
DOI: https://doi.org/10.3969/j.issn.1000-4718.2017.04.028
2017-01-01
Abstract:AIM: To study the effect of ligustrazine on the cardiacmyocyte lesion in rats with type 2 diabetes mellitus.METHODS: Male Wistar rats were injected with STZ via tail vein under high-glucose and high-fat feeding for 4 weeks to establish the animal model of type 2 diabetes mellitus.Ligustrazine at different doses was used to treat the diabetic rats.The body weight, blood glucose and the morphology of heart tissues were observed.The myocardial levels of IL-1β, IL-6 and TNF-α were detected by ELISA, and the protein expression of IKKβ and NF-κB in the myocardium was determined by Westeren blotting.RESULTS: Ligustrazine at high dose alleviated the body weight reduction and blood glucose elevation cause by diabetes, and reduced pro-inflammatory factors IL-1β, TNF-α and IL-6.Moreover, the protein expression of IKKβ and NF-κB was significant decreased by ligustrazine.CONCLUSION: Ligustrazine inhibits the myocardial inflammation caused by diabetes through anti-inflammatory pathway.
What problem does this paper attempt to address?